Novartis announces EC approved Rhapsido for CSU

Novartis (NVS) announced that the European Commission, EC, approved Rhapsido for chronic spontaneous urticaria, CSU, in adult patients with inadequate response to H1-antihistamine treatment. “Today’s approval represents an important advance for CSU patients, offering new hope for faster relief and better day to day disease control. Rhapsido is being developed for multiple immune-mediated conditions in addition to CSU- such as chronic inducible urticaria, food allergy, hidradenitis suppurativa-highlighting the broad potential of a targeted oral BTK pathway approach,” said Patrick Horber, M.D., President, International, Novartis.